Table 3.
Tumour and treatment characteristics
| Less than 6 cycles | Exactly 6 cycles | More than 6 cycles | Exactly 6 cycles—no PD | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PD before end of treatment (N = 567) | No PD before end of treatment (N = 584) | Total (N = 1151) | PD before end of treatment (N = 80) | No PD before end of treatment (N = 475) | Total (N = 555) | PD before end of treatment (N = 66) | No PD before end of treatment (N = 273) | Total (N = 339) | Treatment | |||||
| DOX 75 (N = 223) | DOX 50-IFO 5 (N = 80) | DOX 75-IFO 5 (N = 63) | DOX 75-IFO 10 (N = 109) | Total (N = 475) | ||||||||||
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Histopathological grading | ||||||||||||||
| Grade I and II | 38 (6.7) | 30 (5.1) | 68 (5.9) | 6 (7.5) | 52 (10.9) | 58 (10.5) | 8 (12.1) | 24 (8.8) | 32 (9.4) | 26 (11.7) | 12 (15.0) | 8 (12.7) | 6 (5.5) | 52 (10.9) |
| Grade III | 331 (58.4) | 366 (62.7) | 697 (60.6) | 46 (57.5) | 331 (69.7) | 377 (67.9) | 33 (50.0) | 152 (55.7) | 185 (54.6) | 158 (70.9) | 38 (47.5) | 33 (52.4) | 102 (93.6) | 331 (69.7) |
| Missing | 198 (34.9) | 188 (32.2) | 386 (33.5) | 28 (35.0) | 92 (19.4) | 120 (21.6) | 25 (37.9) | 97 (35.5) | 122 (36.0) | 39 (17.5) | 30 (37.5) | 22 (34.9) | 1 (0.9) | 92 (19.4) |
| Site of primary tumour | ||||||||||||||
| Other | 284 (50.1) | 257 (44.0) | 541 (47.0) | 32 (40.0) | 245 (51.6) | 277 (49.9) | 26 (39.4) | 106 (38.8) | 132 (38.9) | 130 (58.3) | 40 (50.0) | 17 (27.0) | 58 (53.2) | 245 (51.6) |
| Extremities | 129 (22.8) | 143 (24.5) | 272 (23.6) | 27 (33.8) | 152 (32.0) | 179 (32.3) | 17 (25.8) | 73 (26.7) | 90 (26.5) | 76 (34.1) | 15 (18.8) | 12 (19.0) | 49 (45.0) | 152 (32.0) |
| Missing | 154 (27.2) | 184 (31.5) | 338 (29.4) | 21 (26.3) | 78 (16.4) | 99 (17.8) | 23 (34.8) | 94 (34.4) | 117 (34.5) | 17 (7.6) | 25 (31.3) | 34 (54.0) | 2 (1.8) | 78 (16.4) |
| Histology | ||||||||||||||
| Leiomyosarcoma | 192 (33.9) | 180 (30.8) | 372 (32.3) | 23 (28.8) | 128 (26.9) | 151 (27.2) | 25 (37.9) | 79 (28.9) | 104 (30.7) | 66 (29.6) | 25 (31.3) | 13 (20.6) | 24 (22.0) | 128 (26.9) |
| Synovial sarcoma | 32 (5.6) | 59 (10.1) | 91 (7.9) | 10 (12.5) | 71 (14.9) | 81 (14.6) | 6 (9.1) | 29 (10.6) | 35 (10.3) | 37 (16.6) | 8 (10.0) | 7 (11.1) | 19 (17.4) | 71 (14.9) |
| Other | 315 (55.6) | 317 (54.3) | 632 (54.9) | 44 (55.0) | 266 (56.0) | 310 (55.9) | 35 (53.0) | 151 (55.3) | 186 (54.9) | 119 (53.4) | 42 (52.5) | 40 (63.5) | 65 (59.6) | 266 (56.0) |
| Missing | 28 (4.9) | 28 (4.8) | 56 (4.9) | 3 (3.8) | 10 (2.1) | 13 (2.3) | 0 (0.0) | 14 (5.1) | 14 (4.1) | 1 (0.4) | 5 (6.3) | 3 (4.8) | 1 (0.9) | 10 (2.1) |
| Prior surgery | ||||||||||||||
| No surgery | 60 (10.6) | 57 (9.8) | 117 (10.2) | 10 (12.5) | 19 (4.0) | 29 (5.2) | 3 (4.5) | 25 (9.2) | 28 (8.3) | 8 (3.6) | 11 (13.8) | 0 (0.0) | 0 (0.0) | 19 (4.0) |
| Non optimal surgery | 104 (18.3) | 77 (13.2) | 181 (15.7) | 18 (22.5) | 23 (4.8) | 41 (7.4) | 10 (15.2) | 64 (23.4) | 74 (21.8) | 11 (4.9) | 12 (15.0) | 0 (0.0) | 0 (0.0) | 23 (4.8) |
| Complete surgery | 155 (27.3) | 128 (21.9) | 283 (24.6) | 13 (16.3) | 66 (13.9) | 79 (14.2) | 35 (53.0) | 106 (38.8) | 141 (41.6) | 42 (18.8) | 24 (30.0) | 0 (0.0) | 0 (0.0) | 66 (13.9) |
| Unknown | 248 (43.7) | 322 (55.1) | 570 (49.5) | 39 (48.8) | 367 (77.3) | 406 (73.2) | 18 (27.3) | 78 (28.6) | 96 (28.3) | 162 (72.6) | 33 (41.3) | 63 (100.0) | 109 (100.0) | 367 (77.3) |
| Prior radiotherapy | ||||||||||||||
| No | 435 (76.7) | 390 (66.8) | 825 (71.7) | 58 (72.5) | 279 (58.7) | 337 (60.7) | 43 (65.2) | 191 (70.0) | 234 (69.0) | 115 (51.6) | 57 (71.3) | 41 (65.1) | 66 (60.6) | 279 (58.7) |
| Yes | 119 (21.0) | 171 (29.3) | 290 (25.2) | 19 (23.8) | 153 (32.2) | 172 (31.0) | 23 (34.8) | 82 (30.0) | 105 (31.0) | 66 (29.6) | 22 (27.5) | 22 (34.9) | 43 (39.4) | 153 (32.2) |
| Missing | 13 (2.3) | 23 (3.9) | 36 (3.1) | 3 (3.8) | 43 (9.1) | 46 (8.3) | 0 (0) | 0 (0) | 0 (0) | 42 (18.8) | 1 (1.3) | 0 (0.0) | 0 (0.0) | 43 (9.1) |
| Primary site involved | ||||||||||||||
| No | 195 (34.4) | 219 (37.5) | 414 (36.0) | 35 (43.8) | 244 (51.4) | 279 (50.3) | 36 (54.5) | 112 (41.0) | 148 (43.7) | 122 (54.7) | 42 (52.5) | 22 (34.9) | 58 (53.2) | 244 (51.4) |
| Yes | 310 (54.7) | 288 (49.3) | 598 (52.0) | 37 (46.3) | 192 (40.4) | 229 (41.3) | 25 (37.9) | 133 (48.7) | 158 (46.6) | 86 (38.6) | 38 (47.5) | 17 (27.0) | 51 (46.8) | 192 (40.4) |
| Missing | 62 (10.9) | 77 (13.2) | 139 (12.1) | 8 (10.0) | 39 (8.2) | 47 (8.5) | 5 (7.6) | 28 (10.3) | 33 (9.7) | 15 (6.7) | 0 (0.0) | 24 (38.1) | 0 (0.0) | 39 (8.2) |
| Metastatic site involved | ||||||||||||||
| No | 79 (13.9) | 99 (17.0) | 178 (15.5) | 10 (12.5) | 49 (10.3) | 59 (10.6) | 10 (15.2) | 45 (16.5) | 55 (16.2) | 22 (9.9) | 14 (17.5) | 5 (7.9) | 8 (7.3) | 49 (10.3) |
| Yes | 426 (75.1) | 408 (69.9) | 834 (72.5) | 62 (77.5) | 387 (81.5) | 449 (80.9) | 51 (77.3) | 200 (73.3) | 251 (74.0) | 186 (83.4) | 66 (82.5) | 34 (54.0) | 101 (92.7) | 387 (81.5) |
| Missing | 62 (10.9) | 77 (13.2) | 139 (12.1) | 8 (10.0) | 39 (8.2) | 47 (8.5) | 5 (7.6) | 28 (10.3) | 33 (9.7) | 15 (6.7) | 0 (0.0) | 24 (38.1) | 0 (0.0) | 39 (8.2) |